A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19

Michael E. Bowdish(University of Southern California), Annetine C. Gelijns(Icahn School of Medicine at Mount Sinai), Nimesh D. Desai(Hospital of the University of Pennsylvania), Alan J. Moskowitz(Icahn School of Medicine at Mount Sinai), Abhijit Duggal, Michael J. Mack(Baylor Scott & White Health), Mary E. Marks(Boston University), Andrew M. Vekstein, Helena Chang(Icahn School of Medicine at Mount Sinai), Tammie Possemato(University of Southern California), Alexander Iribarne(Dartmouth–Hitchcock Medical Center), Jessica Overbey(Icahn School of Medicine at Mount Sinai), Jonathan Hupf(Institute of Population and Public Health), Sam Parnia(NYU Langone Health), Francis D. Pagani(University of Michigan), Athos J. Rassias(Dartmouth–Hitchcock Medical Center), Beth Hollister(Duke University), Jonathan L. Golob(University of Michigan), Jack Hayes(Mesoblast (United States)), A. Marc Gillinov(Cleveland Clinic), Keren Osman(Tisch Hospital), Patrick T. O’Gara(American College of Cardiology), Silviu Itescu(Mesoblast (United States)), Bradley G. Leshnower(Emory University), Ellen Moquete(Icahn School of Medicine at Mount Sinai), Emilia Bagiella(Columbia University), Eustace Fernandes(Lutheran Medical Group), Peter C. Hou(Brigham and Women's Hospital), Nirav Patel(Northwell Health), Judson B. Williams(WakeMed), Elizabeth Burke(Mesoblast (United States)), Peter K. Smith(Duke University), Christian Romero(University of Southern California), Karen O’Sullivan(Icahn School of Medicine at Mount Sinai), Robert Gottlieb, Fred Grossman, Christina E. Barkauskas(Duke University Hospital)
American Journal of Respiratory and Critical Care Medicine
September 13, 2022
Cited by 71


Related Papers